Non-clear cell renal cell carcinoma: Does the mammalian target of rapamycin represent a rational therapeutic target?

Oncologist

Volumn 17, Issue 8, 2012, Pages 1051-1062

  Albiges, Laurence ^a   Molinie, Vincent ^b   Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SAINT JOSEPH HOSPITAL   (France)

Author keywords

Chromophobe carcinoma; Everolimus; Kidney cancer; Papillary carcinoma; Targeted therapy; Temsirolimus

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; ERLOTINIB; ESTRONE; EVEROLIMUS; FORETINIB; FUMARATE HYDRATASE; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMSIROLIMUS; TUBERIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANEMIA; ASTHENIA; BIRT HOGG DUBE SYNDROME; CANCER PROGNOSIS; CHROMOSOME TRANSLOCATION; DYSPNEA; FATIGUE; GENETIC ANALYSIS; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; MEDULLARY CARCINOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NEPHRON SPARING SURGERY; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SPINDLE CELL CARCINOMA;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84865267038     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0038     Document Type: Review

References (56)

1. National Cancer Institute. SEER stat fact sheets: Kidney and renal pelvis. Available at http://seer.cancer. gov/statfacts/html/kidrp.html. Accessed June 11, 2010.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353:2477-2490.
4. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7: 245-257.
5. Latif F, Mubarak M, Kazi JI. Histopathological characteristics of adult renal tumours: A preliminary report. J Pak Med Assoc 2011;61:224-228.
6. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol 2009;22:S2-S23.
7. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer V. 2.2012. Available at http://www.nccn. org. Accessed June 11, 2010.
8. Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett 2005;10:479-498.
9. Kovacs G, Akhtar M, Beckwith BJ et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131-133.
10. Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006;49:798-805.
11. Heng DY, Choueiri TK. Non-clear cell renal cancer: Features and medical management. J Natl Compr Canc Netw 2009;7:659-665.
12. Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: The 2010 update. Eur Urol 2010;58:398-406.
13. Oosterwijk E, Rathmell WK, Junker K et al. Basic research in kidney cancer. Eur Urol 2011;60:622-633.
14. World Health Organization. Kidney tumors 2004. Available at http://www.iarc.fr/en/publications/pdfsonline/ pat-gen/index.php. Accessed August 29, 2011.
15. Amin MB, Corless CL, Renshaw AA et al. Papillary (chromophil) renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol 1997;21:621-635.
16. Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80: 987-989.
17. Davis CJ, Jr., Mostofi FK, Sesterhenn IA. Renal medullary carcinoma: The seventh sickle cell nephropathy. Am J Surg Pathol 1995;19:1-11.
18. Argani P, Olgac S, Tickoo SK et al. Xp11 translocation renal cell carcinoma in adults: Expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007;31:1149-1160.
19. Malouf GG, Camparo P, Molinie V et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: Clinical features, biological behavior and prognostic factors. J Urol 2011;185:24-29.
20. Escudier B, Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v137-v139.
21. Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: Biological function and target for novel anticancer agents. Am J Health Syst Pharm 2010;67:2095-2106.
22. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: A metabolic disease. Nat Rev Urol 2010;7:277-285.
23. Linehan WM, Bratslavsky G, Pinto PA et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 2010;61:329-343.
24. Land SC, Tee AR. Hypoxia-inducible factor 1-alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007;282:20534-20543.
25. Milella M, Felici A. Biology of metastatic renal cell carcinoma. J Cancer 2011;2:369-373.
26. Tan MH, Wong CF, Tan HL et al. Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer 2010;10:196.
27. Baba M, Furihata M, Hong SB et al. Kidneytargeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008;100:140-154.
28. Looyenga BD, Furge KA, Dykema KJ et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A 2011;108:1439-1444.
29. Argani P, Hicks J, De MarzoAMet al. Xp11 translocation renal cell carcinoma (RCC): Extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 2010;34:1295-1303.
30. Malouf GG, Camparo P, Oudard S et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): A report from the Juvenile RCC Network. Ann Oncol 2010;21:1834-1838.
31. Parikh J, Coleman T, Messias N, Brown J. Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion proteins: A case report and review of literature. Rare Tumors 2009;1:e53.
32. Davies DM, de Vries PJ, Johnson SR et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: A phase 2 trial. Clin Cancer Res 2011;17:4071-4081.
33. Shitara K, Yatabe Y, Mizota A et al. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma. Jpn J Clin Oncol 2011;41:814-816.
34. Bissler JJ, McCormack FX, Young LR et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358: 140-151.
35. Stadler WM, Figlin RA, McDermott DF et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010;116:1272-1280.
36. Beck J, Procopio G, Bajetta E et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: A large open-label study in diverse community settings. Ann Oncol 2011;22:1812-1823.
37. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 2009;10:757-763.
38. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281.
39. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26: 202-209.
40. Grunwald V, Karakiewics PI, Bavbek SE et al. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptortyrosine kinase inhibitor therapy. Eur J Cancer 2012;48:324-332.
41. Blank C, Bono P, Larkin J et al. Safety and efficacy of everolimus in patients with non-clear cell renal cell carcinoma refractory to VEGF-targeted therapy: A subgroup analysis of the REACT expanded-access program. Eur J Cancer 2011;47(suppl 1):abstr 7137.
42. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008;26: 127-131.
43. Gordon MS, Hussey M, Nagle RB et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009;27:5788-5793.
44. Choueiri TK, Vaishampayan UN, Rosenberg JE et al. A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. J Clin Oncol 2012; 30(suppl 5):355.
45. Srinivasan R, Bottaro DP, Choueiri TK et al. Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). J Clin Oncol 2012;30(suppl 5):372.
46. Ravaud A, Oudard S, Gravis-MescamGet al. Firstline sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP). J Clin Oncol 2009;27(suppl 15):5146.
47. Zardavas D, Meisel A, Samaras P et al. Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Rep Oncol 2011;4:16-18.
48. Paule B, Brion N. Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy. Anticancer Res 2011;31:331-333.
49. Larkin JM, Fisher RA, Pickering LM et al. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol 2011;29:e241-e242.
50. Miyake H, Haraguchi T, Takenaka A, Fujisawa M. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol 2011;16:153-155.
51. Ansari J, Fatima A, Chaudhri S et al. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 2009;32:44-46.
52. Numakura K, Tsuchiya N, Yuasa T et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol 2011;16:577-580.
53. Choueiri TK, Mosquera JM, Hirsch MS. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer 2009;7:E93-E94.
54. Hou MM, Hsieh JJ, Chang NJ et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Invest 2010;30:799-804.
55. Choueiri TK, Lim ZD, Hirsch MS et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010;116:5219-5225.
56. de Reijke TM, Bellmunt J, van Poppel H et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 2009;45:765-773.